OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma
Status:
Recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
This is a pilot study exploring the potential benefit of adding OKN-007 with Temozolomide for
treatment in patients with malignant Glioblastoma undergoing adjuvant concomitant
radiotherapy. This drug combination is expected to have an anti-cancer effect in patients who
have experienced disease progression after first line treatment.